PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 261 filers reported holding PACIRA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.85 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $229,000 | -6.9% | 5,615 | -11.9% | 0.01% | 0.0% |
| Q4 2022 | $246,000 | -28.3% | 6,371 | -1.2% | 0.01% | -40.0% |
| Q3 2022 | $343,000 | +6.9% | 6,446 | +17.2% | 0.02% | +15.4% |
| Q2 2022 | $321,000 | -26.7% | 5,502 | -4.1% | 0.01% | -13.3% |
| Q1 2022 | $438,000 | +3.8% | 5,735 | -18.1% | 0.02% | +15.4% |
| Q4 2021 | $422,000 | +6.8% | 7,006 | -0.7% | 0.01% | -7.1% |
| Q3 2021 | $395,000 | -7.3% | 7,057 | +0.6% | 0.01% | 0.0% |
| Q2 2021 | $426,000 | -15.1% | 7,016 | -2.1% | 0.01% | -17.6% |
| Q1 2021 | $502,000 | +15.1% | 7,166 | -1.6% | 0.02% | +13.3% |
| Q4 2020 | $436,000 | -0.7% | 7,282 | -0.4% | 0.02% | -6.2% |
| Q3 2020 | $439,000 | +19.0% | 7,309 | +4.1% | 0.02% | +14.3% |
| Q2 2020 | $369,000 | +13.9% | 7,024 | -27.2% | 0.01% | +7.7% |
| Q1 2020 | $324,000 | – | 9,649 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |